Therapeutic area intelligence for Not applicable with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 3

Companies

Eli Lilly →

Guangdong Hengrui Pharmaceutical Co., Ltd. →

pharmaceutical developers →

Assets

EI-1071 →

SHR-1703 →

Recent signals(3)

ClinicalAugust 5, 2026

First-in-human study of EI-1071 shows safety and tolerability in healthy volunteers

The study evaluated the safety, tolerability, and pharmacokinetics of EI-1071 in healthy volunteers.

ClinicalJuly 17, 2026

Eli Lilly's LY4178256 Tolerance Study in Healthy Participants Initiated

Eli Lilly is conducting a study to evaluate the tolerance and side effects of LY4178256 in healthy participants over approximately 7 months.

ClinicalJuly 16, 2026

Guangdong Hengrui Pharma Compares Delivery Methods for SHR-1703 in Healthy Participants

A clinical study is underway to compare the bioavailability and safety of SHR-1703 Injection using two different delivery methods.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.